FDA approves Mekinist in combination with Tafinlar for advanced melanoma

Authosr(s):

On Jan. 10, the U.S. Food and Drug Administration (FDA) announced it had approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable or metastatic. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here